geranylgeranyl

FGTI-2734 是 有效的RAS C-末端法尼基转移酶 (FT) 和香叶烯基转移酶-1 (GGT-1) 抑制剂，IC50s 分别为 250 nM 和 520 nM。 它可以阻断 KRAS 的膜定位，从而解决 KRAS 耐药性问题，并抑制突变的 KRAS 胰腺肿瘤。

Geranylgeranyl pyrophosphate tetrabutylammonium(1：2)是甲羟戊酸途径产生内源性胆固醇和中间体之一。Geranylgeranyl pyrophosphate tetrabutylammonium(1：2) 香叶基香叶基焦磷酸三铵是二萜类化合物的常见前体，例如紫杉醇，可用于癌症研究。

(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl dihydrogen diphosphate,tetrabutylammonium(1:1.5) 是紫杉二烯，如紫杉醇，的常见前体。

Geranylgeranyl Pyrophosphate triammonium (GGPP triammonium) 是一种参与蛋白质香叶基香叶基化的代谢物，可调节小鼠胚胎血管发生过程中的内皮细胞增殖和凋亡。Geranylgeranyl pyrophosphate triammonium 通过增加 IL-2 表达来放大 T（reg） 分化，以改善 DSS 诱导的结肠炎，可用于研究癌症。

N-acetyl-S-geranylgeranyl-L-Cysteine is a synthetic substrate for the isoprenylated protein methyltransferase (also known as S-adenosylmethionine-dependent methyltransferase). Because it is able to serve as a substrate for the methyltransferase, it effectively functions as an inhibitor of methylation of endogenous isoprenylated proteins.

Geranylgeranyl pyrophosphate, a key metabolite in protein geranylgeranylation, serves as the universal precursor for diterpenoids, such as Paclitaxel. Its role in cancer research stems from this critical function.

S-Geranylgeranyl-L-glutathione是孤儿G蛋白偶联受体（GPCR）P2RY8的配体。该化合物在100 nM浓度下，选择性地诱导P2RY8而非鞘氨醇-1-磷酸受体2（S1P2）、GPR55、半胱氨酸白三烯受体1（CysLT1 receptor）以及CysLT2 receptor的内吞作用。在10 nM浓度下，S-Geranylgeranyl-L-glutathione抑制了表达P2RY8的WEHI-231 B细胞淋巴瘤细胞和分离的人扁桃体生发中心B细胞由趋化因子（C-X-C motif）配体12（CXCL12）诱导的迁移。

Digeranyl bisphosphonate (DGBP) 是一种有效的香叶基焦磷酸香叶酯 (GGPP) 合酶抑制剂，对 Rac1 的香叶基焦磷酸化有抑制作用。Digeranyl bisphosphonate 诱导细胞发生自噬却不诱导细胞凋亡。

GGTI 2147 降低 Rac1 活性，下调 p65 的表达，改善 OGD R 诱导的神经元凋亡。

Perillyl alcohol (Isocarveol) 是一种单萜，可在不影响正常细胞的情况下诱导肿瘤细胞凋亡。

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 1.4 nM and 1.7 μM, respectively.

FTI-2148 is an inhibitor of RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) (IC50s: 1.4 nM and 1.7 μM, respectively).

Geranyl pyrophosphate is an intermediate in the mevalonate pathway. It is formed from dimethylallyl pyrophosphate and isopentenyl pyrophosphate by geranyl pyrophosphate synthase. Geranyl pyrophosphate is used in the biosynthesis of farnesyl pyrophosphate , geranylgeranyl pyrophosphate , cholesterol, terpenes, and terpenoids.

hGGPPS-IN-2 是一种 C-2 取代的噻吩并嘧啶基双膦酸盐 (C2-ThP-BPs) 的类似物，是一种有效的人类香叶基香叶基焦磷酸合成酶 (hGGPPS) 抑制剂。hGGPPS-IN-2 能够靶向作用于多发性骨髓瘤 (MM) 细胞，诱导其选择性凋亡 (apoptosis)，并在体内显示出抗骨髓瘤作用。

GGTI-2166 is a geranylgeranyl transferase I inhibitor. GGTI-2166 inhibit the pOC formation induced by RANKL or TNF-alpha in cultures of both mouse marrow-derived macrophage-colony-stimulating factor (M-CSF) dependent monocytes (MD cells) and the mouse monocyte cell line RAW 264.7 (RAW cells). GGTI-2166 inhibited TRAP activity induced by RANKL or TNF-alpha in both cell cultures and prevented the incorporation of [3H]all-trans geranylgeraniol into prenylated proteins in RAW cells.

hGGPPS-IN-3（Compound 13h）是一种针对人类香叶基香叶基焦磷酸合成酶（hGGPPS）的有效抑制剂，属于C-2取代的噻吩并嘧啶基双膦酸盐（C2-ThP-BPs）衍生物。该化合物能够诱导多发性骨髓瘤（MM）细胞具有选择性地进入凋亡（apoptosis），并且在体内展现了对抗骨髓瘤的活性。

GGTI 2133, a peptidomimetic inhibitor of geranylgeranyl transferase type I (GGTase I; IC50= 38 nM), exhibits 140-fold selectivity towards GGTase I compared to farnesyltransferase (IC50= 5,400 nM). The compound effectively inhibits the geranylgeranylation of RAP1A (IC50= 10 µM) without affecting the farnesylation of H-Ras (IC50= >30 µM). Moreover, GGTI 2133 reduces the growth, migration, and invasion of oral squamous cell carcinoma (OSSC) cells to 75, 45, and 27% of control levels, respectively. When administered intraperitoneally at 5 mg/kg per day, it prevents eosinophil infiltration into the airways in a mouse model of allergic bronchial asthma, although it does not reduce chemokine levels. Additionally, GGTI 2133 thwarts naloxone-induced contraction of ileum in rats experiencing morphine withdrawal syndrome and mitigates the severity of withdrawal symptoms in vivo (ED50= 0.076 mg/kg).